Role of vitamin D in arterial hypertension

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 11, 2010, Pages 1599-1608

  Pilz, Stefan ^a,b   Tomaschitz, Andreas ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

25(OH)D; arterial hypertension; atherosclerosis; calcium; endothelial; randomized controlled trial; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; RENIN; VITAMIN D;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; HYPERTENSION; RADIATION EXPOSURE; RENAL PROTECTION; REVIEW; SYSTOLIC BLOOD PRESSURE; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

BLOOD PRESSURE; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; RISK; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 78649385076     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.142     Document Type: Review

References (123)

1. Mithal A, Wahl DA, Bonjour JP et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 20(11), 1807-1820 (2009).
2. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insuffciency in the US population, 1988-2004. Arch. Intern. Med. 169(6), 626-632 (2009).
3. Holick MF. Vitamin D defciency. N. Engl. J. Med. 357(3), 266-281 (2007).
4. Martins D, Wolf M, Pan D et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 167(11), 1159-1165 (2007).
5. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 6(10), 621-630 (2009).
6. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168(15), 1629-1637 (2008).
7. Pilz S, Dobnig H, Nijpels G et al. Vitamin D and mortality in older men and women. Clin. Endocrinol. (Oxf.) 71(5), 666-672 (2009).
8. Semba RD, Houston DK, Ferrucci L et al. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women. Nutr. Res. 29(8), 525-530 (2009).
9. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromso study. Eur. J. Endocrinol. 162(5), 935-942 (2010).
10. Kilkkinen A, Knekt P, Aro A et al. Vitamin D status and the risk of cardiovascular disease death. Am. J. Epidemiol. 170(8), 1032-1039 (2009).
11. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D defciency and risk of cardiovascular disease. Circulation 117(4), 503-511 (2008).
12. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168(11), 1174-1180 (2008).
13. Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C. Vitamin D and calcium insuffciency-related chronic diseases: an emerging world-wide public health problem. Int. J. Environ. Res. Public Health 6(10), 2585-2607 (2009).
14. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29(6), 726-776 (2008).
15. Lamason RL, Mohideen MA, Mest JR et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafsh and humans. Science 310(5755), 1782-1786 (2005).
16. Yuen AW, Jablonski NG. Vitamin D: in the evolution of human skin colour. Med. Hypotheses 74(1), 39-44 (2010).
17. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol 289(1), F8-F28 (2005).
18. Schuessler M, Astecker N, Herzig G, Vorisek G, Schuster I. Skin is an autonomous organ in synthesis, two-step activation and degradation of vitamin D(3): CYP27 in epidermis completes the set of essential vitamin D(3)-hydroxylases. Steroids 66(3-5), 399-408 (2001).
19. Peterlik M, Cross HS. Vitamin D and calcium insuffciency-related chronic diseases: molecular and cellular pathophysiology. Eur. J. Clin. Nutr. 63(12), 1377-1386 (2009).
20. Blomberg Jensen M, Nielsen JE, Jorgensen A et al. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum. Reprod. 25(5), 1303-1311 (2010).
21. Helvig CF, Cuerrier D, Hosfeld CM et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 78(5), 463-472 (2010).
22. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat. Rev. Endocrinol. 6(2), 83-93 (2010).
23. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110(2), 229-238 (2002).
24. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288(1), E125-E132 (2005).
25. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 103(3-5), 521-524 (2007).
26. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1a-hydroxylase knockout mice. Kidney Int. 74(2), 170-179 (2008).
27. Yuan W, Pan W, Kong J et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 282(41), 29821-29830 (2007).
28. Deb DK, Chen Y, Zhang Z et al. 1,25-dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{k}B pathway. Am. J. Physiol. Renal Physiol. 296(5), F1212-F1218 (2009).
29. Morris KL, Zemel MB. 1,25-dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function. Obes. Res. 13(4), 670-677 (2005).
30. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55(5), 1283-1288 (2010).
31. Tomaschitz A, Pilz S, Ritz E et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta 411(17-18), 1354-1360 (2010).
32. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 74(11), 1394-1402 (2008).
33. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25(3), 320-325 (2008).
34. Lind L, Wengle B, Wide L, Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (acalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am. J. Hypertens. 2(1), 20-25 (1989).
35. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33(1), 73-81 (1999).
36. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J. Clin. Invest. 79(6), 1706-1712 (1987).
37. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann. Intern. Med. 105(5), 649-654 (1986).
38. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr. Osteoporos. Rep. 6(2), 77-83 (2008).
39. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J. Clin. Hypertens. 2(4), 360-370 (1986).
40. Hagström E, Hellman P, Larsson TE et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119(21), 2765-2771 (2009).
41. Pilz S, Tomaschitz A, Drechsler C et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur. Heart J. 31(13), 1591-1598 (2010).
42. Dickinson HO, Nicolson DJ, Cook JV et al. Calcium supplementation for the management of primary hypertension in adults. Cochrane Database Syst. Rev. (2), CD004639 (2006).
43. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat. Rev. Nephrol. 5(12), 691-700 (2009).
44. Jacob AI, Sallman A, Santiz Z, Hollis BW Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 114(7), 1313-1319 (1984).
45. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J. Am. Soc. Nephrol. 20(12), 2631-2639 (2009).
46. Agarwal R, Acharya M, Tian J et al. Antproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 68(6), 2823-2838 (2005).
47. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 54(4), 647-652 (2009).
48. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and infammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52(2), 249-255 (2008).
49. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity J. Mol. Med. 88(5), 441-450 (2010).
50. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83(4), 754-759 (2006).
51. Prietl B, Pilz S, Wolf M et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr. Med. Assoc. J. 12(3), 136-139 (2010).
52. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 76(9), 977-983 (2009).
53. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 75(1), 88-95 (2009).
54. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72(8), 1004-1013 (2007).
55. Drechsler C, Pilz S, Obermayer-Pietsch B et al. Vitamin D defciency is associated with sudden cardiac death, combined cardiovascular events and mortality in haemodialysis patients. Eur. Heart J. 31(18), 2253-22561 (2010).
56. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10(4), 482-496 (2010).
57. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in Type 2 diabetes. A systematic review and meta-ana lysis. J. Clin. Endocrinol. Metab. 92(6), 2017-2029 (2007).
58. Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152(5), 307-314 (2010).
59. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr. Opin. Clin. Nutr. Metab. Care 11(6), 752-757 (2008).
60. Oh J, Weng S, Felton SK et al. 1,25 (OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with Type 2 diabetes mellitus. Circulation 120(8), 687-698 (2009).
61. Chen S, Law CS, Gardner DG. Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J. Steroid Biochem. Mol. Biol. 118(3), 135-141 (2010).
62. Tarcin O, Yavuz DG, Ozben B et al. Effect of vitamin D defciency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 94(10), 4023-4030 (2009).
63. Grant WB. In defense of the sun: an estimate of changes in mortality rates in the United States if mean serum 25-hydroxyvitamin D levels were raised to 45 ng/ml by solar ultraviolet-B irradiance. Dermatoendocrinology 1(4), 207-214 (2009).
64. Grant WB, Mohr SB. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann. Epidemiol. 19(7), 446-454 (2009).
65. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of Type 1 diabetes in 51 regions worldwide. Diabetologia 51(8), 1391-1398 (2008).
66. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30(2 Pt 1), 150-156 (1997).
67. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J. Autoimmun. 34(3), J247-J257 (2010).
68. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. A-melanocyte- stimulating hormone and related tripeptides: biochemistry, antiinfammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated infammatory diseases. Endocr. Rev. 29(5), 581-602 (2008).
69. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D defciency increases the risk of preeclampsia. J. Clin. Endocrinol. Metab. 92(9), 3517-3522 (2007).
70. Haugen M, Brantsaeter AL, Trogstad L et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology 20(5), 720-726 (2009).
71. Forman JP, Giovannucci E, Holmes MD et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49(5), 1063-1069 (2007).
72. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52(5), 828-832 (2008).
73. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 55(3), 792-798 (2010).
74. Wang L, Manson JE, Buring JE, Lee IM, Sesso HD. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 51(4), 1073-1079 (2008).
75. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57(10), 2619-2625 (2008).
76. Young EW, McCarron DA, Morris CD. Calcium regulating hormones in essential hypertension. Importance of gender. Am. J. Hypertens. 3(8 Pt 2), 161S-166S (1990).
77. Sowers MF, Wallace RB, Hollis BW, Lemke JH. Relationship between 1,25-dihydroxyvitamin D and blood pressure in a geographically defned population. Am. J. Clin. Nutr. 48(4), 1053-1056 (1988).
78. Brickman AS, Nyby MD, von Hungen K, Eggena P, Tuck ML. Calcitropic hormones, platelet calcium, and blood pressure in essential hypertension. Hypertension 16(5), 515-522 (1990).
79. St John A, Dick I, Hoad K, Retallack R, Welborn T, Prince R. Relationship between calcitrophic hormones and blood pressure in elderly subjects. Eur. J. Endocrinol. 130(5), 446-450 (1994).
80. Young EW, Morris CD, Holcomb S, McMillan G, McCarron DA. Regulation of parathyroid hormone and vitamin D in essential hypertension. Am. J. Hypertens. 8(10 Pt 1), 957-964 (1995).
81. Lind L, Hänni A, Lithell H, Hvarfner A, Sörensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 8(9), 894-901 (1995).
82. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 30(5), 1289-1294 (1997).
83. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 352(9129), 709-710 (1998).
84. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86(4), 1633-1637 (2001).
85. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur. J. Clin. Nutr. 49(9), 640-646 (1995).
86. Margolis KL, Ray RM, Van Horn L et al. Effect of calcium and vitamin D supplementation on blood pressure: the Womens Health Initiative Randomized Trial. Hypertension 52(5), 847-855 (2008).
87. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet. Med. 26(1), 19-27 (2009).
88. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J. Intern. Med. 267(5), 462-472 (2010).
89. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with Type 2 diabetes: a randomised controlled trial. Diabetologia 53(10), 2112-2119 (2010).
90. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354(7), 669-683 (2006). (Pubitemid 43247138)
91. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-ana lysis. J. Hypertens. 27(10), 1948-1954 (2009).
92. Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure. South. Med. J. 103(8), 729-737 (2010).
93. Chobanian AV, Bakris GL, Black HR et al Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
94. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-ana lysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br. Med. J. 338, b1665 (2009).
95. Pilz S, März W, Wellnitz B et al. Association of vitamin D defciency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93(10), 3927-3935 (2008).
96. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, März W. Vitamin D defciency and myocardial diseases. Mol. Nutr. Food Res. 54(8), 1103-1113 (2010).
97. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152(5), 315-323 (2010).
98. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: a randomised double blind controlled trial. 326(7387), 469 (2003).
99. Hsia J, Heiss G, Ren H et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115(7), 846-854 (2007).
100. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-ana lysis of randomized controlled trials. Arch. Intern. Med. 169(6), 551-561 (2009).
101. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al. Fall prevention with supplemental and active forms of vitamin D: a meta-ana lysis of randomised controlled trials. Br. Med. J. 339, b3692 (2009).
102. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res. 29(9), 3687-3698 (2009).
103. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. Epidemiology of vitamin D insuffciency and cancer mortality. Anticancer Res. 29(9), 3699-3704 (2009).
104. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized controlled trial. Am. J. Clin. Nutr. 85(6), 1586-1591 (2007).
105. Wactawski-Wende J, Kotchen JM, Anderson GL et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354(7), 684-696 (2006). (Pubitemid 43247139)
106. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr. Pract. 15(5), 438-449 (2009).
107. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311(5768), 1770-1773 (2006).
108. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal infuenza A in schoolchildren. Am. J. Clin. Nutr. 91(5), 1255-1260 (2010).
109. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat. Clin. Pract. Rheumatol. 5(2), 99-105 (2009).
110. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, Zittermann A, März W. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr. Drug Targets DOI: 10.2174/1389210207959354501 (2010) (Epub ahead of print).
111. Grant WB. Does vitamin D reduce the risk of dementia? J. Alzheimers Dis. 17(1), 151-159 (2009).
112. Fernandes de Abreu DA, Eyles D, Feron F. Vitamin D: a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34(Suppl. 1), S265-S277 (2009).
113. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-ana lysis of randomized controlled trials. Arch. Intern. Med. 167(16), 1730-1737 (2007).
114. Souberbielle JC, Body JJ, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun. Rev. 9(11), 709-715 (2010).
115. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Beneft-risk assessment of vitamin D supplementation. Osteoporos. Int. 21(7), 1121-1132 (2010).
116. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am. J. Clin. Nutr. 85(1), 6-18 (2007).
117. Heaney RP. Vitamin D in health and disease. Clin. J. Am. Soc. Nephrol. 3(5), 1535-1541 (2008).
118. Lee P, Greenfeld JR, Seibel MJ, Eisman JA, Center JR. Adequacy of vitamin D replacement in severe defciency is dependent on body mass index. Am. J. Med. 122(11), 1056-1060 (2009).
119. Van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H. Cholecalciferol loading dose guideline for vitamin D-defcient adults. Eur. J. Endocrinol. 162(4), 805-811 (2010).
120. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J. Clin. Endocrinol. Metab. 93(9), 3430-3435 (2008).
121. Chel V, Wijnhoven HA, Smit JH, Ooms M, Lips P. Effcacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos. Int. 19(5), 663-671 (2008).
122. Sanders KM, Stuart AL, Williamson EJ et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18), 1815-1822 (2010).
123. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4(9), 1529-1539 (2009).